NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- At the end of the settlement date of February 13, 2026, short interest in 3,595 Nasdaq Global MarketSM securities totaled 15,834,216,597 shares compared with 15,574,683,465 shares in 3,547 Global Market issues reported for the prior settlement date of January 30, 2026. The mid-January short interest represents 2.25 days compared with 2.58 days for the prior reporting period. Short interest in 1,654 securities on The Nasdaq Capital MarketSM totaled 3,724,995,849 sh ...

STRONG FINANCIAL PERFORMANCE, STRATEGIC PORTFOLIO EXPANSION, AND NEW LONG-TERM PPAS, SUPPORT LONG-TERM GROWTH TARGETS HIGHLIGHTS TOTAL REVENUES FOR THE FULL-YEAR AND FOURTH QUARTER INCREASED 12.5% AND 19.6%, RESPECTIVELY, COMPARED TO 2024LONG-TERM PPA AGREEMENTS SIGNED WITH GOOGLE AND SWITCHADVANCING ENHANCED GEOTHERMAL SYSTEMS (EGS) THROUGH SLB JOINT VENTURE AND SAGE INVESTMENT AND COOPERATION AGREEMENTORMAT ANNOUNCES FULL YEAR 2026 OUTLOOK AND GROWTH EXPECTATIONS RENO, Nev., Feb. 25, 2026 (GLOBE NEWSWIRE ...

FOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be participating in the following upcoming investor conferences in March. TD Cowen's 46th Annual Health Care ConferenceFormat: Fireside ChatDate and Time: Monday, March 2, 2026 at 3:50 p.m. ET Location: Boston, MA Leerink Global Healthcare Conference Format: Fireside ChatDate and Time: Monday, M ...

Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid antibody for Alzheimer’s Disease), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson’s Disease) and AL064 (ABC-enabled Tau siRNA for Alzheimer’s Disease) Independent interim futility analysis of the PROGRESS-AD Phase 2 trial of nivisnebart (AL101) in early Alzheimer’s disease expected in the first h ...

ALISO VIEJO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter and full year ended December 31, 2025. Strategic Highlights and Recent Developments 2025 Light Adjustable Lens (LAL® and LAL+®) unit sales increased 12% to 109,615Over 300,000 RxSight LAL procedures performed since launch, reinforcing the benefits of post-operative adjustability in clinical practiceLight Delivery Devices (LDD™) installed base expanded to 1,134, providing a str ...

Global portfolio purchases in 2025 up 4% to $1.41 billion, including $1.17 billion in the U.S.Global collections in 2025 up 20% to $2.59 billion, including $1.95 billion in the U.S.Earnings per share in 2025 of $10.91Repurchased approximately 9% of ECPG shares outstanding for $89.5 million in 2025 SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Encore Capital Group, Inc. (NASDAQ: ECPG), an international specialty finance company, today reported consolidated financial results for the fourth quarter and full yea ...

CHIHUAHUA, Mexico, Feb. 25, 2026 (GLOBE NEWSWIRE) -- GCC, S.A.B. de C.V. (BMV: GCC*), a leading company in the production of cement, aggregates and concrete in the United States and Mexico, today announced the acquisition of three companies and their aggregates, asphalt, and ready-mix concrete operations in El Paso, Texas. This transaction strengthens GCC’s growth strategy by incorporating a platform with approximately US$30 million in annual revenues and reinforcing its operational presence in the El Paso, ...

On track for readout of RASolute 302, a Phase 3 trial of daraxonrasib in second line metastatic PDAC, in first half of 2026Continues to advance broad late-stage pipeline, with five ongoing Phase 3 trials and three additional Phase 3 trials planned to initiate in 2026Expects to substantially complete enrollment in RASolve 301, a Phase 3 trial of daraxonrasib in previously treated NSCLC, this yearInitiated RASolute 305, the first Phase 3 trial for zoldonrasib, in first line metastatic PDAC harboring a RAS G12 ...

SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended December 31, 2025. “In the fourth quarter, we delivered our highest procedure volume to date—approximately 12,200—and sold 65 new systems, marking our strongest capital quarter,” said Larry Wood, Chief Executive Offic ...

CHICAGO and VANCOUVER, British Columbia, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. (“Green Thumb” or the “Company”) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of RISE Dispensaries, today reported its financial results for the fourth quarter and full year ended December 31, 2025. Financial results are reported in accordance with U.S. generally accepted accounting principles (“GAAP”), and all currency is in U.S. dollars. Highlights for ...